Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to observe the distribution of 89Zr-CD147 and
radiation dosimetry characteristics in patients with solid tumors. The secondary objective is
to observe the pharmacokinetic characteristics of 89Zr-CD147 in patients with solid tumors.
This study is a single-center, open-lable study, including 89Zr-CD147 1mCi±10%，89Zr-CD147
3mCi±10% and 89Zr-CD147 5mCi±10% dose group. The trial is expected to last for 2 years from
the first patient signing the consent form to the end of the trial.